Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Issaka Zongo

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|February 13, 2007
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trialIssaka Zongo, Grant Dorsey, Noel Rouamba, et al.
The Pan African Medical Journal|June 16, 2020
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy changeIssaka Zongo, Yves Daniel Compaoré, Frédéric Nikiéma, et al.
Vaccine|June 5, 2007
Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina FasoAdwoa D Bentsi-Enchill, Issaka Zongo, Selma Khamassi, et al.
Antimicrobial Agents and Chemotherapy|March 17, 2010
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoAnyirékun Fabrice Somé, Yves Y Séré, Christian Dokomajilar, et al.
Parasites & Vectors|May 31, 2018
Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina FasoAnyirékun Fabrice Somé, Thomas Bazié, Issaka Zongo, et al.
Parasite (Paris, France)|December 23, 2016
Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina FasoAnyirékun Fabrice Somé, Hermann Sorgho, Issaka Zongo, et al.
Acta Tropica|January 18, 2005
Serodiagnosis of Schistosoma mansoni infections in an endemic area of Burkina Faso: performance of several immunological tests with different parasite antigensHermann Sorgho, Mahmoud Bahgat, Jean-Noel Poda, et al.
Antimicrobial Agents and Chemotherapy|July 10, 2013
The polymorphic linker domain of pfmdr1 is associated with resistance-conferring mutations in Plasmodium falciparum populations from East and West AfricaJohn Okombo, Issaka Zongo, Nahla Gadalla, et al.
Malaria Journal|May 4, 2017
Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccineBrian Greenwood, Alassane Dicko, Issaka Sagara, et al.
Tropical Medicine & International Health : TM & IH|February 6, 2014
Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trialHalidou Tinto, Salou Diallo, Issaka Zongo, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|February 13, 2007
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trialIssaka Zongo, Grant Dorsey, Noel Rouamba, et al.
The Pan African Medical Journal|June 16, 2020
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy changeIssaka Zongo, Yves Daniel Compaoré, Frédéric Nikiéma, et al.
Vaccine|June 5, 2007
Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina FasoAdwoa D Bentsi-Enchill, Issaka Zongo, Selma Khamassi, et al.
Antimicrobial Agents and Chemotherapy|March 17, 2010
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoAnyirékun Fabrice Somé, Yves Y Séré, Christian Dokomajilar, et al.
Parasites & Vectors|May 31, 2018
Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina FasoAnyirékun Fabrice Somé, Thomas Bazié, Issaka Zongo, et al.
Parasite (Paris, France)|December 23, 2016
Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina FasoAnyirékun Fabrice Somé, Hermann Sorgho, Issaka Zongo, et al.
Acta Tropica|January 18, 2005
Serodiagnosis of Schistosoma mansoni infections in an endemic area of Burkina Faso: performance of several immunological tests with different parasite antigensHermann Sorgho, Mahmoud Bahgat, Jean-Noel Poda, et al.
Antimicrobial Agents and Chemotherapy|July 10, 2013
The polymorphic linker domain of pfmdr1 is associated with resistance-conferring mutations in Plasmodium falciparum populations from East and West AfricaJohn Okombo, Issaka Zongo, Nahla Gadalla, et al.
Malaria Journal|May 4, 2017
Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccineBrian Greenwood, Alassane Dicko, Issaka Sagara, et al.
Tropical Medicine & International Health : TM & IH|February 6, 2014
Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trialHalidou Tinto, Salou Diallo, Issaka Zongo, et al.
Pageof 7